Page last updated: 2024-12-09
6-o-(n-heptylcarbamoyl)methylglucoside
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
6-O-(N-heptylcarbamoyl)methylglucoside: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 2733955 |
SCHEMBL ID | 60345 |
MeSH ID | M0168177 |
Synonyms (30)
Synonym |
---|
alpha-d-glucopyranoside, methyl, 6-(heptylcarbamate) |
6-o-(n-heptylcarbamoyl)methylglucoside |
115457-83-5 |
unii-72l66t594h |
72l66t594h , |
6-o-(n-heptylcarbamoyl)methyl-alpha-d-glucopyranoside |
hecameg |
methyl 6-o-(n-heptylcarbamoyl)-alpha-d-glucopyranoside, >=97.0% (tlc) |
[(2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-methoxyoxan-2-yl]methyl n-heptylcarbamate |
SCHEMBL60345 |
AKOS024375418 |
.alpha.-d-glucopyranoside, methyl, 6-(heptylcarbamate) |
6-o-(n-heptylcarbamoyl)-methyl-.alpha.-d-glucopyranoside |
methyl-.alpha.-d-glucopyranoside 6-(heptylcarbamate) |
hecameg [mi] |
6-o-(n-heotylcarbamoyl)-methyl-alpha-d-glucopyranoside |
mfcd00077425 |
DTXSID00151107 |
methyl 6-o-(n-heptylcarbamoyl)-i+/--d-glucopyranoside |
methyl 6-o-(n-heptylcarbamoyl)-alpha-d-glucopyranoside |
methyl-6-o-(n-heptylcarboxyl)-a-d-glucopyranoside |
AS-67710 |
methyl-alpha-d-glucopyranoside 6-(heptylcarbamate) |
CS-0256375 |
a-d-glucopyranoside,methyl,6-(heptylcarbamate) |
((2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-methoxytetrahydro-2h-pyran-2-yl)methyl heptylcarbamate |
Q27266084 |
A893870 |
6-o-(n-heptylcarbamoyl)-methyl-a-d-glucopyranoside |
HY-W250182 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (6)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (16.67) | 18.7374 |
1990's | 2 (33.33) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 1 (16.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.35
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.35) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |